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Binary values were obtained using a threshold, which based on
the mean survival time of patients derived from literature.
RESULTS: Back-propagation as well as fuzzy-logic neural net-
works were applied. A 10-fold cross validation method was used
to obtain the appropriate models. Final results were compared
with the generic, logistic regression-based model. The best pre-
diction score of the ANN model was 82% (generalization) and
was higher than logistic regression prediction rate. Best obtained
model was tested under its practical application in the in-silico
study to model switching from cisplatin to carboplatin therapy
in NSCLC. The results demonstrate that thanks to the better sur-
vival rate such operations could be cost-effective. CONCLU-
SIONS: Artiﬁcial Neural Networks could be applied in
pharmacoeconomics analysis as additional modeling tools.
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OBJECTIVES: To analyze the risk of re-hospitalization for
COPD following different treatment regimens. METHODS: A
retrospective cohort study with data from the Dutch PHARMO
system, including medication and hospital admission records of
1.6 million inhabitants of 34 Dutch cities was performed.
Patients >40yrs with a ﬁrst admission for COPD during
1992–2002 were identiﬁed. Treatment was assessed in the period
of 90 days following ﬁrst discharge. Cox proportional hazard
analysis was performed to analyze the time to re-hospitalization
for COPD for different treatment regimes. Hazard rate (HR) and
95% conﬁdence intervals (CI) were adjusted for potential risk
factors including gender, age, year of hospitalization and disease
severity. The maximum follow-up time was two years.
RESULTS: From the total cohort of 3855 patients, 1118 (29%)
were re-hospitalized within two years after the ﬁrst hospitaliza-
tion. The mean period to re-hospitalization was 230 days. Com-
pared to ICS as a reference group, an increased risk for
re-hospitalization was found in the following treatment groups:
theophylline (HR 1.83, CI 1.12–2.99), and ICS combined with
anticholinergics and beta-agonists (HR 1.50, CI 1.02–2.20).
CONCLUSIONS: This study found re-hospitalizations occurred
in approximately one-third (1/3) of patients. Differences in
COPD re-hospitalization risks between treatment groups were
observed. Anti-inﬂammatory therapy alone demonstrated a sig-
niﬁcant protective effect compared to theophylline therapy alone
or a combination therapy of ICS, anticholinergics and beta-
agonists.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(COPD)—Methods and Concepts
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ITEM SELECTION FOR COPD-SPECIFIC UTILITY
INSTRUMENT
Meguro M, Jones PW
St George’s Hospital Medical School, London, UK
OBJECTIVE: To identify items in the existing disease-speciﬁc St.
George’s Respiratory Questionnaire (SGRQ) that might be suit-
able for use in a COPD speciﬁc utility instrument. METHOD:
The SGRQ has three domains. We planned to use three items per
domain (mild, moderate and severe) for the new instrument.
Using data from 893 patients we ﬁrst reduced the original 50
SGRQ items to the 40 “best” items using classical test methods
and Rasch modelling (RUMM 2010 software). The Person Sep-
aration Index for these 40 items was 0.9 (an “excellent” ﬁt to a
unidimensional model). We then used Rasch location maps to
identify suitable items. We examined those items that covered
95% of the patients, then divided the population into tertiles
according to their person location value: mild (mean location 
-0.97 logits, SD = 0.35), moderate (mean location 0.09 logits,
SD = 0.39), severe (mean location 1.45 logits, SD = 0.56). For
each level of patient severity we chose one item per SGRQ
domain using criteria based upon quality of ﬁt of the item to the
unidimensional model of all 40 items. RESULTS: We were able
to identify one suitable item per domain at each severity level.
The locations of the nine items ranged from -1.16 logits to 1.47
logits. The mean item location for the three mild items was 
-0.55 logits, moderate items 0.18 logits, severe items 1.16 logits.
CONCLUSION: We have now identiﬁed nine items from three
domains of health in COPD. Each item has a clearly deﬁned level
of severity. This approach should ensure that the utility instru-
ment, when fully developed, has good discriminative properties
and may also have good evaluative properties.
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OBJECTIVES: The purpose of this study is to establish a
measure of the COPD severity using claims data. METHODS:
The study sample was identiﬁed from a large claims database
covering the period 1999–2002. Patients of age 18–65 with pre-
vious acute exacerbation of COPD (AECB) were included in 
the study sample (n = 2068). Variables associated with COPD
severity were extracted. Variables with low face validity, high
endorsement rate (>97%), or low homogeneity (measured by
Chronbach’s alpha) were excluded. Principal component analy-
sis with orthogonal solution was conducted to identify the latent
severity score. Scree test and eigenvalue-one criterion were used
to determine the number of latent factors. The severity score was
standardized (mean = 50, SD = 10). Construct validity was tested
by comparing severe COPD patients to moderate/mild patients
of 3-month AECB incidence rate and by comparing the failure
rate (ER/hospitalization) of antibiotic treatment in AECB.
RESULTS: Six variables were excluded from the original 18
potential variables due to low face validity or high endorsement
rate. Principal component analysis based on the remaining 12
variables produced a single latent factor (eigenvalue = 3.6), there-
fore no factor rotation was performed. The score loaded high on
the use of oxygen therapy, corticosteroids, and bronchodilators,
etc. The resulting factor loading agreed with the clinical recom-
mendation in GOLD criteria of treating COPD by severity.
Chronbach’s alpha test showed good homogeneity of the sever-
ity score (0.71) and no input variables were rejected. The con-
struct validity tests showed that, compared with mild/moderate
COPD patients, severe patients were about 3 times more likely
to have AECB episodes and 60% more likely to have antibiotic
treatment failure in AECB episodes. CONCLUSIONS: The
COPD severity score developed in this study can be applied to a
wide range of retrospective studies of COPD, where results from
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the usually accepted measure of COPD severity categorization,




THE COST-EFFECTIVENESS OF IRBESARTAN IN THE
TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS
WITH MICROALBUMINURIA IN TAIWAN
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OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy and costs in Taiwan of
treating patients with diabetes, hypertension, and microalbu-
minuria (DHM) with either standard hypertension treatment
alone or standard hypertension treatment plus irbesartan 300mg
daily. METHODS: A peer-reviewed, published Markov model
that simulated progression from microalbuminuria to nephropa-
thy, doubling of serum creatinine, ESRD, and all-cause mortal-
ity in patients with DHM was adapted to Taiwan. Three
strategies were compared: A) early use of irbesartan (i.e. start
treatment in subjects with microalbuminuria) versus B) late use
of irebesartan (i.e. as from overt nephropathy), or C) standard
hypertension care (with comparable blood pressure control).
Cumulative incidence of ESRD, costs and life expectancy were
projected for a hypothetical cohort of 1000 subjects. Treatment-
speciﬁc progression and mortality probabilities were derived
from published trials: IRMA-2 (in microalbuminuria) and IDNT
(in overt nephropathy). Medical management and cost data per
state were obtained from published local sources. A ﬂexible time
horizon up to 25-years and third party payer perspective were
used. Future costs and LE were discounted at 3% yearly.
RESULTS: When compared to standard blood pressure control,
early irbesartan was projected to reduce the cumulative incidence
of ESRD from (mean ± standard deviation) 22% to 8%, save
TN $248,302 (US $7303), and add 0.702 life years per treated
patient. Late irbesartan was dominant to control but dominated
by early irbesartan. The superiority of early use of irbesartan
over standard care was robust for most variables, except for the
cost of dialysis and the time horizon. Break-even occurred after
12 years. CONCLUSIONS: Treating DHM patients with early
irbesartan was projected to reduce the incidence of ESRD, extend
life and reduce costs. Treating patients at a later stage is still ben-
eﬁcial, however to a lower extent. Applying ﬂexible time hori-
zons shows additional relevant information to decision makers.
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ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY
HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR
TRIAL: AN EVIDENCE-BASED MEDICINE (EBM) APPROACH
Edwards SJ, Hadlow S
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OBJECTIVES: To determine the number needed to treat (NNT)
for one additional patient to achieve the Joint European Task
Force 1998 goal for low-density lipoprotein cholesterol (LDL-C)
of <3.0mmol/L (116mg/dL) at 6 weeks for rosuvastatin 10mg
compared to atorvastatin, pravastatin and simvastatin. Patients
included in the Statin Therapies for Elevated Lipid Levels com-
pared Across doses to Rosuvastatin (STELLAR) trial had an
initial LDL-C ≥ 4.1mmol/L (160mg/dL) and <6.5mmol/L 
(250mg/dL). METHODS: Data on patients achieving the Euro-
pean 1998 LDL-C goal with rosuvastatin and the other statins
were extracted and recalculated using an intention to treat (ITT)
approach where all patients randomised were included in the
analysis and any dropouts were assumed to be treatment fail-
ures. The ITT analysis formed the basis of the NNT calculations.
Negative NNT’s were interpreted as inﬁnity. RESULTS: The
NNT’s for rosuvastatin 10mg compared to the other statins are:
atorvastatin 10mg (3.9, 95%CI: 2.8 to 6.3), 20mg (9.5, 95%CI:
4.9 to 135.8); 40mg (361.1 in favour of atorvastatin, 
95%CI: 10.7 to inﬁnity); 80mg (17.7 in favour of atorvastatin,
95%CI: 7.2 to inﬁnity); simvastatin 10mg (1.9, 95%CI: 1.6 to
2.3), 20mg (3.1, 95%CI: 2.3 to 4.4); 40mg (6.7, 95%CI: 4.0 to
19.8), 80mg (67.4, 95%CI: 9.4 to inﬁnity); pravastatin 10mg
(1.4, 95%CI: 1.2 to 1.5), 20mg (1.6, 95%CI: 1.4 to 1.8); 40mg
(1.9, 95%CI: 1.6 to 2.4). In applying NNT’s, the numbers should
be rounded up, e.g. an NNT of 3.9 means that you need to treat
4 patients with rosuvastatin 10mg rather than atorvastatin 10
mg to get one additional patient to the LDL-C goal at six weeks.
CONCLUSIONS: NNT’s are the “currency” of EBM with an
NNT < 40 considered beneﬁcial in chronic conditions. In this
context, rosuvastatin 10mg has an advantageous NNT proﬁle
compared to the available doses of other statins.
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Majority of patients treated for hyperlipidemia with available
cholesterol lowering drugs (LLD) do not achieve recommended
LDL-C goal in Spain. OBJECTIVES: To assess LDL-C reduction
and goal attainment over time and determine time period when
patients are most likely to attain goal after initiation of LLD in
Spain. METHODS: Retrospective cohort study conducted at 23
primary care centres and 16 outpatient lipid centres. Eligible
patients were adults (≥18 years) with CHD/CHD equivalent or
2+ major risk factors (2 + RF) prior to ﬁrst prescription of LLD
between January 1998–April 1999, and +36 months of follow-
up data after. LDL-C goals were based on NCEP III guidelines
(100mg/dl for CHD/CHD equivalent patients, 130mg/dl for 2 +
RF group). Goal attainment analyses were based on proportion
of patients at goal from those with a valid LDL-C measure at 3
month time intervals from therapy start, and on increase or
decrease in that proportion for subsequent periods. RESULTS:
A total of 619 patients (46% CHD/CHD equivalent and 54%
nonCHD with 2 + RFs) were included in the study. Mean age
was 60 years (SD 10.22), 48% were female. Statins were initial
LLD in 90% patients. Only 20% CHD and 29% 2 + RF patients
were at goal at study end. Proportion of patients at goal
increased to 23% after 3 months of therapy start and remained
stable afterwards around 25%. Increase in proportion of patients
at goal was only positive (+23%) for the ﬁrst 3 months (p < 0.05)
and then remained around 0% increase till study end. CON-
CLUSIONS: Percentage of patients at goal only increased during
ﬁrst three month period after start of lipid lowering therapy,
remaining ﬂat there-after. More aggressive lipid lowering therapy
should be started for those not at goal after ﬁrst 3 months from
LLD start, to enable more patients to get to LDL-C goal.
